FDA Clearance Tracker · P200019
VENTANA MMR RxDx Panel
Last checked: Nov 20, 2026Latest source record: Apr 22, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Apr 22, 2021
Approved
Time to decision
402 days
Received Mar 16, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P200019
- Device name
- VENTANA MMR RxDx Panel
- Applicant
- Ventana Medical Systems
- Applicant location
- Tucson, AZ
- Received
- Mar 16, 2020
- Decided
- Apr 22, 2021
- Decision
- Approved
- Supplements
- 12 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Regulation
- 21 CFR 864.1860
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Ventana MMR RxDx Pavel as a CDx for identifying patients with endometrial cancer with dMMR status who may benefit from treatment with Jemperli.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QNH (Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Ventana Medical Systems
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
P990081-S060 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
P250031 · Decided Jun 12, 2026 · 298 days after receipt
Device type: Immunohistochemistry Assay, Antibody (SHF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.